1.53
2.33%
0.03
전일 마감가:
$1.50
열려 있는:
$1.53
하루 거래량:
544.53K
Relative Volume:
0.32
시가총액:
$251.70M
수익:
$314.00K
순이익/손실:
$-40.23M
주가수익비율:
-5.4643
EPS:
-0.28
순현금흐름:
$-84.71M
1주 성능:
+1.66%
1개월 성능:
+13.70%
6개월 성능:
+0.99%
1년 성능:
-17.03%
Atai Life Sciences N V Stock (ATAI) Company Profile
명칭
Atai Life Sciences N V
전화
49 89 2153 9035
주소
WALLSTRASSE 16, BERLIN
ATAI을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
1.535 | 251.70M | 314.00K | -40.23M | -84.71M | -0.28 |
VRTX
Vertex Pharmaceuticals Inc
|
440.94 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
682.54 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
663.74 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
275.41 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
121.25 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-11-18 | 재확인 | H.C. Wainwright | Buy |
2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
2022-11-01 | 개시 | Loop Capital | Buy |
2021-11-30 | 개시 | Maxim Group | Buy |
2021-11-11 | 개시 | ROTH Capital | Buy |
2021-10-18 | 개시 | H.C. Wainwright | Buy |
2021-09-01 | 개시 | Jefferies | Buy |
2021-07-13 | 개시 | Berenberg | Buy |
2021-07-13 | 개시 | Canaccord Genuity | Buy |
2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
2021-07-13 | 개시 | Citigroup | Buy |
2021-07-13 | 개시 | Cowen | Outperform |
2021-07-13 | 개시 | Credit Suisse | Outperform |
2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Atai Life Sciences N V 주식(ATAI)의 최신 뉴스
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst (NASDAQ:ATAI) - Seeking Alpha
Atai Life Sciences Reports Positive Topline Results From Alcohol Use Disorder Treatment Study - Marketscreener.com
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder - Yahoo Finance
Atai Life Sciences N.V. Announces Resignation of Michael Auerbach as Member of the Supervisory Board of Directors and Supervisory Board?s Compensation Committee - Marketscreener.com
ATAI Life Sciences supervisory board member resigns - MSN
ATAI Life Sciences Board Member Resignation and Changes - TipRanks
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Srinivas Rao Assumes the Role of Sole CEO of Atai Life Sciences N.V -January 10, 2025 at 07:00 am EST - Marketscreener.com
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health - Yahoo Finance
I: TechBio Weekly News - substack.com
US Penny Stocks To Consider In December 2024 - Simply Wall St
Thiel-Backed Psychedelic Firm Atai to Buy Stake in Beckley - MSN
Optimizing atai Life Sciences’ Banking Structure to Drive Growth - Citi
Atai Life Sciences stock target cut, retains buy rating on developments - Investing.com India
Oxbridge Re Holdings Among 3 US Penny Stocks To Watch - Simply Wall St
RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up - Seeking Alpha
Atai Life Sciences Advances Psychedelic Treatments in Q3 2024 - TipRanks
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times
Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
atai Life Sciences Advances Psychedelic Pipeline as FDA Clears DMT Depression Treatment | ATAI Stock News - StockTitan
374Water And 2 Other Promising US Penny Stocks To Watch - Yahoo Finance
Are ATAI Life Sciences N.V.’shares a good deal? - US Post News
Insider Sale Alert: ATAI Life Sciences N.V. [ATAI] – Is it Time to sell? - Knox Daily
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - StockTitan
Selling Buzz: ATAI Life Sciences N.V. [ATAI] 10% Owner ATAI Life Sciences N.V. sells 2,660,000 shares of the company - Knox Daily
ATAI Life Sciences N.V. (ATAI)’s results reveal risk - US Post News
Maxim Group gives a Buy recommendation for ATAI Life Sciences N.V. (ATAI) - Knox Daily
ATAI Life Sciences completes acquisition of IntelGenx Corp. - Investing.com India
ATAI Life Sciences completes acquisition of IntelGenx Corp. By Investing.com - Investing.com South Africa
10% Owner ATAI Life Sciences N.V. sale 2,660,000 shares of ATAI Life Sciences N.V. [ATAI] - Knox Daily
ATAI Life Sciences N.V. (ATAI) stock analysis: A comprehensive overview - US Post News
Trading Day Review: ATAI Life Sciences N.V. (ATAI) Loses Momentum, Closing at 1.16 - The Dwinnex
A History of Outperforming Analyst Forecasts and Beating the Odds: ATAI Life Sciences N.V. (ATAI) - SETE News
Maxim Group Upgrades ATAI Life Sciences N.V. (ATAI) to a Buy from a Hold - Knox Daily
Life Sciences N.V. Atai Sells 2,660,000 Shares of COMPASS Pathways plc (NASDAQ:CMPS) Stock - MarketBeat
Atai Life Sciences executives sell shares valued at $16 million - Investing.com India
Deeper Dive: Understanding ATAI Life Sciences N.V. (ATAI) Through its Various Ratios - The Dwinnex
ATAI Life Sciences N.V. (ATAI) deserves closer scrutiny - US Post News
ATAI Life Sciences N.V. [ATAI] Shares Fall Approximately -7.81% Over the Year - Knox Daily
TWKS SPECIAL ALERT: Thoughtworks Shareholders Seeking More Than $4.40 Per Share Contact Julie & Holleman Regarding Sale to Apax - PR Newswire
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
T2 Biosystems Achieves Successful Defense of Patent for - GlobeNewswire
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology - StockTitan
Magic mushroom market set to go gangbusters, Irish researcher says - Mugglehead
ATAT’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Australian Clinical Labs Shareholder Stake Shifts - TipRanks
(ATAT) Trading Advice - Stock Traders Daily
T2 Biosystems director sells shares worth $133 - Investing.com India
Atour Lifestyle Holdings Ltd ADR (ATAT) is looking forward to a strong quarter - SETE News
Atai Life Sciences N V (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):